Research and development expense

12 Months Ended

Dec. 31, 2016

Research and development expense Disclosure [Abstract]

Research and Development expense Disclosure [Text Block]

14. Research and development expense:

In June 2015, the Company entered into a license and supply agreement with SteadyMed Ltd. for the distribution rights to TREVYENT^® that included an upfront payment of $3,000 upon execution of the agreement which was recorded in R&D expense.